ABIONYX Pharma Balance Sheet Health
Financial Health criteria checks 3/6
ABIONYX Pharma has a total shareholder equity of €4.8M and total debt of €4.3M, which brings its debt-to-equity ratio to 89.8%. Its total assets and total liabilities are €13.8M and €9.0M respectively.
Key information
89.8%
Debt to equity ratio
€4.31m
Debt
Interest coverage ratio | n/a |
Cash | €1.93m |
Equity | €4.79m |
Total liabilities | €9.04m |
Total assets | €13.83m |
Financial Position Analysis
Short Term Liabilities: ABNX's short term assets (€5.8M) exceed its short term liabilities (€5.7M).
Long Term Liabilities: ABNX's short term assets (€5.8M) exceed its long term liabilities (€3.3M).
Debt to Equity History and Analysis
Debt Level: ABNX's net debt to equity ratio (49.5%) is considered high.
Reducing Debt: ABNX's debt to equity ratio has reduced from 143.4% to 89.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABNX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ABNX has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.1% each year.